UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 21, 2018
Aileron Therapeutics, Inc.
(Exact Name of Company as Specified in Charter)
| Delaware | 001-38130 | 13-4196017 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 281 Albany Street Cambridge, MA |
02139 | |||
| (Address of Principal Executive Offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: (617) 995-0900
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.07 Submission of Matters to a Vote of Security Holders.
Aileron Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 21, 2018. The following is a summary of the matters voted on at that meeting.
| (a) | The stockholders of the Company elected Jeffrey A. Bailey, John H. McArthur, D.B.A., and Jodie P. Morrison as Class I directors for a three-year term ending at the annual meeting of stockholders to be held in 2021. The results of the stockholders’ vote with respect to the election of the Class I directors was as follows: |
| Name |
For | Withheld | Broker Non-Votes |
|||||||||
| Jeffrey A. Bailey |
8,647,744 | 53,347 | 4,339,742 | |||||||||
| John H. McArthur, D.B.A. |
8,603,429 | 97,662 | 4,339,742 | |||||||||
| Jodie P. Morrison |
8,594,065 | 107,026 | 4,339,742 | |||||||||
| (b) | The stockholders of the Company ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018. The results of the stockholders’ vote with respect to such ratification were as follows: |
| For |
Against |
Abstain |
Broker Non-Votes | |||
| 12,999,486 |
40,232 | 1,115 | — |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Aileron Therapeutics, Inc. | ||||||
| Date: August 17, 2018 | By: | /s/ Donald Dougherty | ||||
| Donald Dougherty | ||||||
| Chief Financial Officer | ||||||